{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:46:27Z","timestamp":1782589587326,"version":"3.54.5"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","phiro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physics and Imaging in Radiation Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.phro.2026.100996","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T14:30:35Z","timestamp":1778423435000},"page":"100996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Improved organs-of-interest dose reduction potential with intensity modulated proton therapy and breath-hold in mediastinal lymphoma"],"prefix":"10.1016","volume":"39","author":[{"given":"Bastiaan D.P.","family":"Ta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.M.","family":"Canters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"van der Klugt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Vilches-Freixas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Kneepkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur","family":"Vereijken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Cobben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indra","family":"Lubken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cissy","family":"Stultiens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije","family":"Velders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Verstappen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyanne","family":"Tholen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne G.H.","family":"Niezink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk K.M.","family":"De Ruysscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"Berb\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phro.2026.100996_b0005","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO-24-01373","article-title":"Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial results","volume":"42","author":"Martelli","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0010","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2013.51.7524","article-title":"[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 study","volume":"32","author":"Martelli","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0015","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2016.09.031","article-title":"Positron Emission Tomography\/Computed Tomography Assessment after Immunochemotherapy and Irradiation using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma","volume":"97","author":"Ceriani","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100996_b0020","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1182\/blood.2019004296","article-title":"Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach","volume":"136","author":"Hayden","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.phro.2026.100996_b0025","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early Positron Emission Tomography Response-adapted Treatment in stage I and II Hodgkin Lymphoma: final results of the Randomized EORTC\/LYSA\/FIL H10 Trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0030","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2019s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial","volume":"385","author":"Behringer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.phro.2026.100996_b0035","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0040","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced Treatment Intensity in patients with Early-Stage Hodgkin\u2019s Lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phro.2026.100996_b0045","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin\u2019s Lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phro.2026.100996_b0050","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0055","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.phro.2026.100996_b0060","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.phro.2026.100996_b0065","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin\u2019s Lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phro.2026.100996_b0070","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2005.05.022","article-title":"Salvage radiotherapy in patients with relapsed and refractory Hodgkin\u2019s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group","volume":"23","author":"Josting","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0075","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2014.09.041","article-title":"Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma","volume":"91","author":"Tseng","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100996_b0080","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/jnci\/djaa194","article-title":"Long-Term Cause-specific Mortality in Hodgkin Lymphoma patients","volume":"113","author":"De Vries","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.phro.2026.100996_b0085","doi-asserted-by":"crossref","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-06-1420","article-title":"Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin\u2019s lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up","volume":"12","author":"Brusamolino","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.phro.2026.100996_b0090","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ijrobp.2017.05.004","article-title":"Evidence-based Review on the use of Proton Therapy in Lymphoma from the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee","volume":"99","author":"Tseng","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100996_b0095","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin\u2019s disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102248","article-title":"Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma","volume":"9","author":"Geurts","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.phro.2026.100996_b0105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"Van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0110","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv008","article-title":"Risk for valvular heart disease after treatment for Hodgkin lymphoma","volume":"107","author":"Cutter","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.phro.2026.100996_b0115","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"Van Nimwegen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.phro.2026.100996_b0120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.clon.2015.03.005","article-title":"Involved Node, Site, Field and Residual volume Radiotherapy for Lymphoma: a Comparison of Organ at Risk Dosimetry and Second Malignancy risks","volume":"27","author":"Murray","year":"2015","journal-title":"Clin Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0125","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second Cancer Risk up to 40 Years after Treatment for Hodgkin\u2019s Lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.phro.2026.100996_b0130","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/jnci\/95.13.971","article-title":"Roles of Radiation Dose, Chemotherapy, and Hormonal Factors in Breast Cancer following Hodgkin\u2019s Disease","volume":"95","author":"Van Leeuwen","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.phro.2026.100996_b0135","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/jnci\/djac125","article-title":"Radiotherapy-Related Dose and Irradiated volume Effects on Breast Cancer Risk among Hodgkin Lymphoma Survivors","volume":"114","author":"Roberti","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.phro.2026.100996_b0140","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.radonc.2013.06.041","article-title":"Long-term risk of secondary skin cancers after radiation therapy for Hodgkin\u2019s lymphoma","volume":"109","author":"Dani\u00ebls","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0145","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijrobp.2015.01.013","article-title":"Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both?","volume":"92","author":"Aznar","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100996_b0150","article-title":"Deep inspiration breath hold versus free breathing technique in mediastinal radiotherapy for lymphoma","volume":"3","author":"Anne Houlihan","year":"2021","journal-title":"BJR Open"},{"key":"10.1016\/j.phro.2026.100996_b0155","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/0284186X.2014.932435","article-title":"Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: Benefit of deep inspiration breath-hold","volume":"54","author":"Petersen","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0160","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.radonc.2018.08.017","article-title":"Comparison of butterfly volumetric modulated arc therapy to full arc with or without deep inspiration breath hold for the treatment of mediastinal lymphoma","volume":"129","author":"Starke","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0165","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210618","article-title":"The role of motion management and position verification in lymphoma radiotherapy","volume":"94","author":"Aznar","year":"2021","journal-title":"Br J Radiol"},{"key":"10.1016\/j.phro.2026.100996_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109734","article-title":"ESTRO-ACROP guideline: Recommendations on implementation of breath-hold techniques in radiotherapy","volume":"185","author":"Aznar","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109594","article-title":"Radiotherapy for mediastinal lymphoma in breath hold using surface monitoring and nasal high flow oxygen: Clinical experiences and breath hold stability","volume":"183","author":"Canters","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0180","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.ijrobp.2011.05.015","article-title":"Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin\u2019s lymphoma","volume":"82","author":"Paumier","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.phro.2026.100996_b0185","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.prro.2019.05.009","article-title":"Comparison of Techniques for Involved-Site Radiation Therapy in patients with lower Mediastinal Lymphoma","volume":"9","author":"Everett","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0190","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.prro.2013.07.015","article-title":"Active breathing control for patients receiving mediastinal radiation therapy for lymphoma: Impact on normal tissue dose","volume":"4","author":"Charpentier","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0195","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2022.10.003","article-title":"Systematic review for deep inspiration breath hold in proton therapy for mediastinal lymphoma: a PTCOG Lymphoma Subcommittee report and recommendations","volume":"177","author":"Patel","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0200","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.radonc.2017.07.033","article-title":"Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: the impact of proton therapy and\/or deep inspiration breath hold","volume":"125","author":"Rechner","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0205","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13014-018-1066-2","article-title":"Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation","volume":"13","author":"Baues","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0210","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.prro.2019.01.006","article-title":"Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: which patients Benefit the Most?","volume":"9","author":"Ntentas","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0215","first-page":"1","article-title":"Reducing heart dose with protons and cardiac substructure sparing for mediastinal lymphoma treatment","volume":"7","author":"Taparra","year":"2021","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.phro.2026.100996_b0220","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13014-019-1432-8","article-title":"Comparative photon and proton dosimetry for patients with mediastinal lymphoma in the era of Monte Carlo treatment planning and variable relative biological effectiveness","volume":"14","author":"Tseng","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0225","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.adro.2020.08.004","article-title":"Effect of Deep Inspiration Breath hold on Normal Tissue Sparing with Intensity Modulated Radiation Therapy Versus Proton Therapy for Mediastinal Lymphoma","volume":"5","author":"Moreno","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0230","unstructured":"International Commission on Radiation Units and Measurements (ICRU). Prescribing, Recording, and Reporting Proton-Beam Therapy. ICRU Report No. 78. 2007. https:\/\/www.icru.org\/report\/prescribing-recording-and-reporting-proton-beam-therapy-icru-report-78\/."},{"key":"10.1016\/j.phro.2026.100996_b0235","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.radonc.2019.08.005","article-title":"Practical robustness evaluation in radiotherapy \u2013 a photon and proton-proof alternative to PTV-based plan evaluation","volume":"141","author":"Korevaar","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0240","series-title":"Dutch National Indication Protocol for Proton Therapy","author":"Boersma","year":"2022"},{"key":"10.1016\/j.phro.2026.100996_b0245","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clon.2021.12.007","article-title":"Model-based selection for Proton Therapy in Breast Cancer: Development of the National Indication Protocol for Proton Therapy and first Clinical Experiences","volume":"34","author":"Boersma","year":"2022","journal-title":"Clin Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0250","doi-asserted-by":"crossref","DOI":"10.1002\/acm2.13512","article-title":"Small spot size versus large spot size: effect on plan quality for lung cancer in pencil beam scanning proton therapy","volume":"23","author":"Rana","year":"2022","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.phro.2026.100996_b0255","unstructured":"Cartechini G, Kneepkens E, Vilches-Freixas G, Lubken I, Velders M, Nijsten S, et al. In vivo and predictive interplay evaluation methodology for lung and esophageal cancer patients treated in free breathing with IMPT. Unpublished Results."},{"key":"10.1016\/j.phro.2026.100996_b0260","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071788","article-title":"The Influence of Motion on the delivery Accuracy when Comparing actively Scanned Carbon Ions versus Protons at a Synchrotron-based Radiotherapy Facility","volume":"14","author":"Lebbink","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.phro.2026.100996_b0265","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/0284186X.2018.1512153","article-title":"Comparative treatment planning study for mediastinal Hodgkin\u2019s lymphoma: impact on normal tissue dose using deep inspiration breath hold proton and photon therapy","volume":"58","author":"Edvardsson","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0270","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2340\/1651-226X.2024.23964","article-title":"Pencil beam scanning proton therapy for mediastinal lymphomas in deep inspiration breath-hold: a retrospective assessment of plan robustness","volume":"63","author":"H\u00f6rberger","year":"2024","journal-title":"Acta Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0275","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.radonc.2022.02.015","article-title":"Technical challenges in the treatment of mediastinal lymphomas by proton pencil beam scanning and deep inspiration breath-hold","volume":"169","author":"Righetto","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0280","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.canrad.2024.04.002","article-title":"Radiation exposure of the glandular mammary tissue in women patients with mediastinal Hodgkin lymphoma treated with protons","volume":"28","author":"Loap","year":"2024","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.phro.2026.100996_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110931","article-title":"Proton beam therapy for mediastinal Hodgkin lymphoma: a prospective study of clinical efficacy and safety","volume":"208","author":"D\u011bde\u010dkov\u00e1","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0290","doi-asserted-by":"crossref","unstructured":"Ta B, Hutschemaekers S, Crijns A, Pisciotta P, Canters R, Vilches Freixas G, et al. OC-0294 Proton therapy in mediastinal lymphoma patients in a nationwide cohort, using model-based selection. Radiother Oncol - ESTRO 2022 Abstract Book 2022;170:S256\u20137. https:\/\/www.sciencedirect.com\/journal\/radiotherapy-and-oncology\/vol\/170\/suppl\/S1 (accessed April 9, 2026).","DOI":"10.1016\/S0167-8140(22)02552-X"},{"key":"10.1016\/j.phro.2026.100996_b0295","doi-asserted-by":"crossref","unstructured":"Vilches Freixas G, van der Klugt K, Canters R, Kneepkens E, Vereijken F, Cobben M. E25-3577 Breath-Hold Proton Therapy for Mediastinal Lymphoma with Surface Scanning and Nasal High-Flow: One Year Clinical Experience. Radiother Oncol - ESTRO 2025 Abstract Book 2025;2026:S3317\u20139. https:\/\/www.sciencedirect.com\/journal\/radiotherapy-and-oncology\/vol\/206\/suppl\/S1 (accessed April 9, 2026).","DOI":"10.1016\/S0167-8140(25)01808-0"},{"key":"10.1016\/j.phro.2026.100996_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110998","article-title":"Selection of patients for proton therapy to reduce risk of second primary lung and breast cancer","volume":"210","author":"Boersma","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.phro.2026.100996_b0305","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.phro.2026.100996_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmp.2024.104890","article-title":"Proton therapy of lung cancer patients \u2013 Treatment strategies and clinical experience from a medical physicist\u2019s perspective","volume":"130","author":"Taasti","year":"2025","journal-title":"Phys Med"},{"key":"10.1016\/j.phro.2026.100996_b0315","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Physics and Imaging in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405631626000965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405631626000965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:27:22Z","timestamp":1782588442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405631626000965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":63,"alternative-id":["S2405631626000965"],"URL":"https:\/\/doi.org\/10.1016\/j.phro.2026.100996","relation":{},"ISSN":["2405-6316"],"issn-type":[{"value":"2405-6316","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved organs-of-interest dose reduction potential with intensity modulated proton therapy and breath-hold in mediastinal lymphoma","name":"articletitle","label":"Article Title"},{"value":"Physics and Imaging in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phro.2026.100996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society of Radiotherapy & Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100996"}}